Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade–resistant Melanoma for Anti-PD-L1 Rechallenge

PURPOSE: Drug repurposing offers the opportunity for chemotherapy to be used to reestablish sensitivity to immune checkpoint blockade (ICB) therapy. Here we investigated the clinical and translational aspects of an early phase II study of azacitidine and carboplatin priming for anti-PDL1 immunothera...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Westhuizen, Andre, Lyle, Megan, Graves, Moira C., Zhu, Xiaoqiang, Wong, Jason W. H., Cornall, Kerrie, Ren, Shu, Pugliese, Leanna, Levy, Richard, Majid, Adeeb, Vilain, Ricardo E., Bowden, Nikola A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010343/
https://www.ncbi.nlm.nih.gov/pubmed/36923309
http://dx.doi.org/10.1158/2767-9764.CRC-22-0128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010343/
https://www.ncbi.nlm.nih.gov/pubmed/36923309
http://dx.doi.org/10.1158/2767-9764.CRC-22-0128

Ejemplares similares